In 27 of 29 participants whose responses were evaluated a few weeks after the infusion, a high-sensitivity test could detect no trace of their cancer in their bone marrow. The CAR T cells eliminated cancers anywhere in the body they appeared. Credit: © kukhunthod / Fotolia
‘Extraordinary’ but short-term results from early-stage trial of engineered immune cells.27 of29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells were genetically engineered with a synthetic receptor molecule called a CAR (for chimeric antigen receptor) that empowers the T cells to recognize and kill cancer cells with marker CD19.
This trial was designed to evaluate the safety of administering the engineered cells and to lay t...
Read More
Recent Comments